Understanding supports for cancer stem-like cells in malignant glioma may suggest therapeutic strategies for their elimination. Here we show that the Toll-like receptor TLR9 is elevated in glioma stem-like cells (GSC) where it contributes to glioma growth. TLR9 overexpression is regulated by STAT3 which was required for GSC maintenance. Stimulation of TLR9 with a CpG ligand (CpG ODN) promoted GSC growth, whereas silencing TLR9 expression abrogated GSC development. CpG-ODN treatment induced Frizzled4-dependent activation of JAK2, thereby activating STAT3. Targeted delivery of siRNA into GSC was achieved via TLR9 using CpG-siRNA conjugates. Through local or systemic treatment, administration of CpG-Stat3 siRNA to silence STAT3 in vivo reduced GSC along with glioma growth. Our findings identify TLR9 as a functional marker for GSC and a target for the delivery of efficacious therapeutics for glioma treatment.
Introduction
Malignant glioma remains one of the most deadly cancers (1) . Despite improved surgical procedures and newer therapies, no significant improvement of patients' survival has been observed, underscoring the urgency and importance to identify approaches that are not derivatives of current treatment modalities. One of the subpopulations of glioma cells has been recognized as highly tumorigenic and resistant to various therapies (2, 3) . This subpopulation of glioma cells exhibits stem cell-like phenotype -capable of sustaining self-renewal with gene expression profiles that resemble those of multipotent neural stem cells. Owing to their resemblance to normal stem cells, these aggressive cancer cells are referred to as cancer stem cells (CSCs) (4, 5) . In addition to glioma, CSCs have been shown in several other types of solid tumors, as well as blood cancers (6) . While there are still unanswered issues and questions on the etiology of CSCs, the importance to eliminate glioma stem cells (GSCs) for achieving better antitumor efficacy is evident.
One of the most crucial factors underlying cancer is Signal Transducer and Activator of Transcription 3 (STAT3). As a signal transducer, STAT3 is a central node for numerous oncogenic signaling pathways involving cytokines and growth factors (7) (8) (9) (10) . STAT3 is also an important transcription regulator, defining a transcriptional program at multiple levels that facilitates tumor cell proliferation, survival, invasion, cancer-promoting inflammation and suppression of antitumor immune responses (7, 9, (11) (12) (13) (14) . Furthermore, an essential role of STAT3 in maintaining expression of genes important for stem cell phenotype has been demonstrated (15) . For malignant glioma, persistent activation of a STAT3-regulated gene network is critical for tumor progression, mesenchymal transition, and negatively impacts patient survival (16) . Highly relevant to the current study, findings from pioneering work have suggested the importance of targeting STAT3 and/or its critical upstream activators in disruption of GSC maintenance (16) (17) (18) . However, directly targeting STAT3 with small-molecule drugs for the treatment of cancer patients remains a challenge, due to the lack of enzymatic activity of transcription factors.
Toll-like receptor 9 (TLR9) is expressed in several types of immune cells (19) (20) (21) . Stimulation by its ligands, single-stranded unmethylated DNA containing CpG oligodinucleotides (CpG-ODNs), in the immune subsets has been shown to activate the NF-κB pathway, leading to Th1 immunostimulation and antitumor immune responses, especially in conjunction with other modality of therapies, including radiation (22) (23) (24) . However, antitumor immune responses induced by CpG-ODN monotherapy are less than desirable in several pre-clinical testing models and disappointing in some human trials (22, 25) . One of the explanations for the limited antitumor immune responses induced by CpG-ODN treatment is that the CpG-TLR9 signaling axis also activates STAT3, which serves as a brake to constrain CpG-induced Th1 immune responses (23) . The ability of STAT3 to potently suppress Th1 immune responses and antitumor immunity has been well documented (10, 26) .
We have recently developed an in vivo siRNA delivery technology platform by covalently linking siRNA to the CpG moiety recognized by TLR9. We have demonstrated that CpG-STAT3siRNA treatment in vivo silences STAT3 in dendritic cells, macrophages, and B cells, leading to potent antitumor immunity (27) . Our recent data further illustrate that silencing STAT3 in myeloid cells by CpG-STAT3siRNA resulted in antitumor effects at both primary tumor and future metastatic sites (14, 27, 28) . While a role of TLR9 in stimulating immune responses has been recognized (21, 29) , expression of TLR9 in tumors, including malignant glioma, correlates with poor patient survival (30, 31) . TLR2 and TLR7 have also been shown to promote tumor growth in a STAT3-dependent manner (32) . In the current study, we investigate the possibility that TLR9 has a critical role in promoting GSCs, in turn, also allows inhibition of essential but difficult targets critical for CSC development and maintenance.
buffer (Complete-mini, Roche). For immunoprecipitation, antibodies were coupled to rProteinG Agarose beads (Invitrogen) prior to adding them to the cell lysates. Precipitation was performed overnight shaking at 4°C, then complexes were carefully washed, and proteins were electrophoretically separated by SDS-PAGE followed by Western blot detection using antibodies raised against TLR9, Sox2, MSI-1 (abcam), pStat3, Stat3, Nestin (Santa Cruz), JAK2 (Cell Signaling Technologies), tubulin, β-actin (Sigma), and anti-Frizzled 4 used for pulldown was obtained from Santa Cruz.
Sphere Formation of Cell Lines and Treatments. Sphere formation was induced by subculturing cells in DMEM-F50-50 supplemented with HEPES (Gibco), B-27 (Invitrogen), Heparin-sodium (Sagent), antibiotics and antimicotics (Gibco), 20 ng/ml FGFb, 20 ng/ml EGF (Peprotech), and GlutaMAX (Gibco). Cell culture was performed in ultra-low adhesion plates (Corning). Primary human GSC-like lines were subcultured using Accutase (Innovative Cell Technologies, Inc) to break up sphere clusters. Spherical cell clusters were treated for 24 hours with 500 pmol/ml CpG-ODN (class A) 5'-GGG GAC GAC:GTC GTG GGG GGG-3', CpG-ODN (class B) 5'-TCG TCG TTT TGT CGT TTT GTC GTT-3', CpG-ODN (class C) 5'-TCG TCG TCG TTC:GAA CGA CGT TGA T-3' purchased from InvivoGen or 500 pmol/ml CpG-ODN-D19 (class A) 5'-GGT GCA TCG ATG CAG GGG GG-3' kindly provided by Dr. Piotr Swiderski of City of Hope. Interferon-γ was purchased from Peprotech; GSCs were treated with 20 ng/ml for 30 min at 37°C. RNAi against human Frizzled4 (FZD4) was introduced using RNAiMAX according to the manufacturer's instructions (Invitrogen). Frizzled-4siRNA was obtained from Santa Cruz (sc-39983).
Flow Cytometry. Antibodies for flow cytometry were purchased from Santa Cruz (MSI-1, SOX2, Nestin), Cell Signaling Technologies (pJAK2), Abcam (GFAP, Tuj1), R&D Systems (oligodendrocyte marker O4) or BD Pharmingen (pSTAT3, TLR9). Secondary antibodies used were coupled to either Alexa Fluor 647 or Alexa Fluor 488 (Invitrogen). Intracellular staining was performed after fixation of single cell suspensions with 2% paraformaldehyde and permeabilization with ice-cold 100% methanol, blocked with PBS/1% BSA for 1h at 4°C, and stained with an antibody diluted at 1:50 in PBS/1% BSA for 30 -45 min at room temperature. ALDH1 detection was performed according to the manufacturer's instructions (Aldefluor, StemCell Technologies). Stained single cell suspensions were analyzed using an AccuriC6 cytometer (BD Biosciences), followed by FlowJo 7.6.1 analysis.
Imaging. Indirect immunofluorescence on frozen tissue sections or paraffin embedded tissue specimen was carried out as previously described (28) . Briefly, after deparaffinization and antigen retrieval at low pH citrate buffer (Vector), tissue microsections were fixed with 2% paraformaldehyde, followed by permeabilization with ice-cold 100% methanol, treated with signal enhancer (Image-iT, Invitrogen) for 30 min, blocked with PBS containing 10% goat serum and 2.5% mouse serum (Sigma) for 1h at room temperature, and stained with a 1:50 dilution of the primary antibody (TLR9, MSI-1, Sox2, Nestin, GFAP, Tuj1 antibodies were obtained from abcam; pStat3, Frizzled 4 were purchased from Santa Cruz; pJak2, cleaved caspase 3 antibodies were obtained from Cell Signaling Technologies; anti-mouse CD31 was purchased from BD Pharmingen; anti-oligodendrocyte marker O4 was obtained from R&D Systems) in PBS/sera overnight at 4°C. After washing with PBS, secondary antibodies were diluted 1:100 in PBS/sera containing 100 ng/ml Hoechst33342 (Invitrogen). After final washing with PBS, specimens were mounted with Mowiol (Calbiochem).
Indirect immunofluorescence on cultured cells was carried out as described previously (27) . Confocal analysis was performed using a LSM510 Meta (Zeiss). Intravital multiphoton imaging was performed as previously described (27) . Blood vasculature of the brain was stained by systemic injection of 100 μg dextran-rhodamine (Invitrogen), cell apoptosis was visualized by systemically injecting 10 μg Annexin V-FITC (BioVision) diluted in sterile HBSS (Gibco). We used an Ultima 2photon microscope for IVMPM analysis (Prairie Technologies). Acquired Z-stacks were reconstructed to full 3D view using Amira software (Visualization Sciences Group). Non-invasive imaging of luciferase-expressing glioma cells using D-luciferin was performed according to the manufacturer's instructions (Caliper Life Science, Perkin-Elmer). Bioluminescence given by luciferase activity was acquired using IVIS100 imaging systems and analyzed with Living Image 2.50 (Caliper Life Science, Perkin-Elmer).
Chromatin Immunoprecipitation Assay. Chromatin immunoprecipitation was performed using a ChIP assay kit (Upstate Biotechnology) according to the manufacturer's instructions. We performed chromatin immunoprecipitation in cells based on the protocol provided by Upstate Biotechnology. The chromatin was prepared from 5 x 10 6 cells and subjected to ChIP assay as previously described (13).
4 μg of anti-STAT3 rabbit polyclonal antibody or control rabbit IgG were used for immunoprecipitation. Limiting-Dilution Assay (LDA). Cells were cultured for at least 10 days in sphere forming medium.
Prior to sphere assays, cells were placed into single cell suspension. Cultures free of clumping and being of ≥ 90% viability were used. Cells were serially diluted from 500 to 2 cells per well into 96-well plates as previously described (33) . Cells were cultured in DMEM-50-50 supplemented with HEPES (Gibco), B-27 supplement (Life Technologies), Pen-Strep Antibiotics (Life Technologies). Every three days, fresh EGF and bFGF (PeproTech) were added. Subsequently, cultures were analyzed for spheres in each well. Data were analyzed using the Extreme Limiting Dilution Algorithm (ELDA) (34) . 
Statistical Analyses

Results
TLR9 is overexpressed in glioma stem cells
Elevated TLR9 expression has been shown to correlate with poor survival of malignant glioma patients (30, 31) . We therefore tested TLR9 expression levels in GSC subpopulations of glioblastoma tumors. Overexpression of TLR9 as well as high expression levels of phospho-STAT3 (pSTAT3) could be found in well-characterized primary, low-passage human GSC-like cells derived from highgrade gliomas (35, 36) (Fig. 1A and data not shown). Increased TLR9 expression was associated with considerably enhanced expression levels of critical factors favoring GSC maintenance and progeny such as SOX2, Musashi-1 (MSI1) and Nestin. Conversely, low expression of TLR9 was concomitant with reduced expression of SOX2, MSI1 and Nestin in primary human GSCs ( Our data show that CpG-ODNs activate STAT3 (23) . Because JAK2 is a tyrosine kinase contributing to STAT3 activation, we examined whether CpG-ODN could activate JAK2. We treated human primary GSCs with various classes of CpG-ODNs, followed by flow cytometric analysis for JAK2 phosphorylation. Data obtained from these experiments showed that treatment with CpG-ODNs for 24 h activates JAK2 effectively, which was comparable to the immediate early response induced by IFN-γ ( Fig. 2A) . We next explored the molecular mechanism(s) by which CpG-ODN/TLR9 signaling activates JAK2/STAT3. Since Wnt/Frizzled class receptor 4 (Frizzled 4) signaling is critical for cancer stem cell maintenance and has been shown to be important for GSC stemness (38, 39), we hypothesized that CpG/TLR9 signaling may, directly or indirectly, stimulate the Wnt/Frizzled pathway.
We showed that silencing Frizzled 4 ( Fig. 2B ) dramatically inhibited pJAK2 and pSTAT3 levels ( (Fig. 2E, upper panels) . Interestingly, Frizzled 4 and pJAK2 were localized in the same subcellular domains upon CpG-ODN stimulation (Fig. 2E, lower panels) . Furthermore, immunoprecipitation with an anti-Frizzled 4 antibody followed by Western blotting to detect JAK2
showed that JAK2 and Frizzled 4 were in the same complex upon CpG-ODN stimulation (Fig. 2F) .
CpG-STAT3siRNA inhibits human GSC-like cells and human glioblastoma growth
We next investigated whether a human version of CpG-STAT3siRNA (40) diminishes the GSC phenotype in GBM. To assess whether undifferentiated populations can be pushed toward differentiation, human primary GSCs (35, 36) were treated in vitro with CpG-ODN or CpGSTAT3siRNA and analyzed via confocal microscopy for expression of cell differentiation markers.
Upon treatment with CpG-STAT3siRNA cell differentiation markers O4, GFAP, and Tuj1 were substantially increased compared to those of CpG-ODN and non-treated controls. Interestingly, primary human GSCs treated with CpG-ODN reduced O4 expression (Fig. 3A,B) . Moreover, while CpG-ODN treatment stimulated tumor sphere growth (Fig. 3A, middle panel) , administration of CpGSTAT3siRNA resulted in disruption of tumor sphere integrity (Fig. 3A, right panel) .
TLR9 is necessary to maintain murine GSC-like phenotype ( Supplementary Fig. S2 ). To determine if STAT3 is necessary for maintaining human GSC phenotype, primary human GSC cells were treated with CpG-STAT3siRNA and placed into a limiting dilution assay to determine the frequency of cancer stem cells within a tumor cell population (33, 34, 41) . Treatment of primary human GSCs with CpGSTAT3siRNA resulted in a significant decrease in the ability of GSC populations to form sphere cultures upon extreme dilution of cells plated, suggesting a reduction in GSC frequency upon treatment (Fig. 3C) . We further assessed the effects of CpG-STAT3siRNA on expression of an enzymatic cancer stem cell marker, aldehyde dehydrogenase 1 (ALDH1). Using a fluorescent substrate of ALDH, bodipy-aminoacetaldehyde, a substantial decrease in ALDH1 + cells was observed upon introduction of CpG-STAT3siRNA as analyzed in two different primary human GSC-lines (Fig.   3D ).
We next determined the effects of in vivo treatment with CpG-STAT3siRNA of primary human glioma cells enriched for the GSC phenotype ex vivo prior to engraftment. Primary human GSCs were implanted in immuno-deficient (NSG) mice to form tumors. Treatment with CpG-STAT3siRNA resulted in a significant delay in tumor growth compared to the non-treated and CpG-ODN treated controls (Fig. 3E) . When analyzed for inhibition of pSTAT3 via confocal microscopy, pSTAT3 levels were considerably decreased in CpG-STAT3siRNA treated human GSC primary cells when compared to CpG-ODN treated and non-treated controls (Fig. 3F, upper panels) . Furthermore, tumor apoptosis was increased, as shown by enhanced cleaved caspase-3 expression (Fig. 3F, middle panel), and proliferative activity indicated by Ki67 was significantly decreased in the CpG- 
STAT3siRNA treated cells compared to controls (Fig. 3F, lower panels) . These data indicate a significant therapeutic effect on glioblastoma highly enriched with GSC-like cells when treated with CpG-STAT3siRNA in vivo. Since the siRNA in the conjugate is against human STAT3, and the mice used in the experiments are severely immune-deficient, the antitumor effects observed are likely due to direct effects on the human glioblastoma/GSC-like cells in vivo, which are also supported by results generated in vitro (Fig. 3A-D) . Moreover, the anti-tumoral efficacy of CpG-Stat3siRNA could be validated in rodent models (Supplementary Fig. S3 ) and a significantly reduced expression of factors involved in GSC maintenance, such as Sox2 and SSEA1, could be confirmed in mouse tumors when mice were treated with CpG-Stat3siRNA ( Supplementary Fig. S4 ).
Systemic delivery of CpG-Stat3siRNA targets GSC in orthotopic brain tumor
Local treatments with CpG-Stat3siRNA of subcutaneous glioma resulted in inhibition of tumor growth and Stat3 activity, induction of tumor cell apoptosis, as well as prolonged survival (Supplementary Fig.   S3 ). The local treatment also decreased expression of CSC-associated factors (Supplementary Fig.   S4 ). However, the blood-brain barrier represents a major obstacle for therapeutic intervention for brain tumors. After systemic injection, fluorescently-labeled CpG-Stat3siRNA could be found in an intact, tumor-free brain as fast as 2 hours after administration (Fig. 4A) , and appeared to internalize into cells (Fig. 4B) . Systemically treating mice bearing luciferase-expressing tumors with CpGluciferase-siRNA also showed that the CpG-siRNA could pass the blood-brain barrier to reach the tumor ( Supplementary Fig. S5 ). Furthermore, systemic CpG-Stat3siRNA treated mice had a significantly prolonged survival compared to the control groups (Fig. 4C) . A concomitant decrease in Stat3 activity and TLR9 expression, compared to CpG-scrambled-RNA treatments, was observed (Fig. 4D) . Moreover, systemic treatments of orthotopically engrafted brain tumors with CpGStat3siRNA drastically reduced the expression of Nestin, Msi1 as well as pStat3 (Fig. 4E) . 
